The following is a summary of “Anticoagulation and Antiplatelet Therapy for Atrial Fibrillation and Stable Coronary Disease: ...

Overall, however, the net clinical benefit—based on an endpoint incorporating all stroke and systemic embolism, MI, cardiovascular death, and major bleeding—tends to lean toward giving the DOAC versus ...

With no differences between single or dual antiplatelet therapy or anticoagulants at 6 months, an RCT is warranted for ...

Under the terms of the agreement, Kyorin will receive $55m upfront and will be eligible for milestone payments of up to ...

Growth and income investors who stayed with some of Wall Street's favorite high-yield dividend stocks have had reason to ...

The rise in Biocon share price came after the company announced that its wholly-owned subsidiary, Biocon Pharma, has received final approvals for Lenalidomide capsules and Dasatinib tabs from USFDA ...

William Blair upped their Q2 2025 earnings estimates for Bristol-Myers Squibb in a note issued to investors on Tuesday, March ...

an oral inhibitor indicated for the reduction in risk of stroke/systemic embolism in NVAF and for the treatment of DVT/PE Orencia for adult patients with active RA and psoriatic arthritis ...

Novartis NVS announced that the FDA has approved Fabhalta (iptacopan) for a third indication. The regulatory body approved ...

The company’s products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE; Opdivo for various anti-cancer ...

Medical experts reveal the 5 most common causes of sudden death, their warning signs, and what you can do to reduce your risk ...

High-risk acute pulmonary embolism affects around five percent ... of the pulmonary circulation by means of intrahospital systemic thrombolysis, surgical thrombectomy or percutaneous catheter ...